Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $288 million public offering of common stock by Juno Therapeutics, Inc. Juno’s common stock is traded on the NASDAQ under the symbol “JUNO.”

Based in Seattle, Washington, Juno is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer.

The Davis Polk corporate team included partner Bruce K. Dallas and associates Marcus K. Hintze and Dylan Service. Partner Rachel D. Kleinberg and associate Catherine L. Chu provided tax advice. Counsel Michelle Ontiveros Gross and associate Jason J. Bang provided intellectual property and technology advice. Members of the Davis Polk team are based in the Northern California and New York offices.